42
Participants
Start Date
November 30, 2008
Primary Completion Date
December 31, 2011
Study Completion Date
December 31, 2011
Nimotuzumab
the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.
Radiotherapy
the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)
The Affiliated tumour hosiptal of HARBIN Medical University, Harbin
Wuhan Union Hospital, Wuhan
Qilu Hospital,Shandong University, Jinan
Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Lead Sponsor
Biotech Pharmaceutical Co., Ltd.
OTHER